# Plan de cuenta de Sanofi

> Biofarmacéutica con sede en París (inmunología, enfermedades raras, vacunas): 43.626 millones de euros de ventas en 2025, con Dupixent, y 74.846 empleados.

## De un vistazo

Sanofi es un grupo biofarmacéutico con sede en París que informa de un único segmento, Biopharma, gestionado a través de Specialty Care, General Medicines y Vaccines, con una investigación centrada en la inmunología. Tiene operaciones en unos 60 países, vende en más de 160 y es la novena farmacéutica del mundo; Estados Unidos representó el 50,8 % de las ventas de 2025. Las ventas netas del ejercicio 2025 fueron de 43.626 millones de euros (+9,9 % a tipos de cambio constantes), el resultado operativo de las actividades de 12.149 millones de euros y el beneficio neto IFRS de 7.813 millones de euros, con Dupixent solo en 15.714 millones de euros. La plantilla era de 74.846 personas a finales de 2025, tras la desconsolidación del negocio de salud del consumidor Opella en abril de 2025; Sanofi conserva el 48,2 %.

## Unidades de negocio

- **Specialty Care**: Inmunología, enfermedades raras, neurología y oncología, con productos como Dupixent (15.714 millones de euros en 2025, con Regeneron), ALTUVIIIO, Nexviazyme, Ayvakit y Sarclisa. Tenía 8.291 empleados a finales de 2025 y está dirigida por Manuela Buxo desde el 1 de marzo de 2026.
- **General Medicines**: Marcas consolidadas como Lantus, Toujeo, Plavix, Lovenox y Praluent, además de Rezurock y Tzield, con 19 centros industriales. Los productos maduros sufren la erosión por genéricos y biosimilares y recortes de precios en Estados Unidos. Thomas Grenier la dirige desde el 1 de septiembre de 2026.
- **Vaccines** (7.936 millones de euros de ventas netas en el ejercicio 2025): Polio/tos ferina/Hib y refuerzos, gripe y COVID-19, Beyfortus (VRS, con AstraZeneca) y vacunas contra la meningitis, del viajero y de enfermedades endémicas, vendidas a gobiernos y a compradores como UNICEF y GAVI. Las ventas cayeron un 1,2 % a tipos de cambio constantes en 2025 y la adquisición de Dynavax aportó Heplisav-B en 2026. Dirigida por Thomas Triomphe hasta que pase a dirigir China el 1 de septiembre de 2026.

## Prioridades estratégicas

- **Maximizar Dupixent**: Se espera que Dupixent alcance unos 25 mil millones de euros en 2030; un plan Defend, Extend, Innovate busca protegerlo más allá del vencimiento de la patente estadounidense del compuesto en marzo de 2031, incluida la dosificación cada cuatro semanas.
- **Hacer crecer los lanzamientos farmacéuticos**: Los lanzamientos farmacéuticos apuntan a unos 10 mil millones de euros en 2030 y a 5,2-5,3 mil millones en 2026, con ALTUVIIIO, Sarclisa, Ayvakit, Nexviazyme y Rezurock a la cabeza.
- **Corregir la productividad de I+D**: La consejera delegada Belén Garijo ha puesto en marcha una revisión del portfolio «de fuera hacia dentro» que ya ha eliminado amlitelimab, itepekimab y balinatunfib, y quiere más rigor científico en las decisiones de paso de la fase 2 a la fase 3.
- **Intensificar el desarrollo de negocio y las fusiones y adquisiciones**: Sanofi podría invertir hasta 15 mil millones de euros este año en desarrollo de negocio y fusiones y adquisiciones manteniendo su calificación AA, centrándose en dermatología, respiratorio y enfermedades raras; las operaciones mayores son una opción.
- **Recuperar impulso en China**: Thomas Triomphe dirige China desde el 1 de septiembre de 2026, para vender en el mercado y obtener licencias de innovación china.
- **Eficiencia impulsada por IA**: La plataforma de decisión Plai la usan más de 22.000 empleados y la herramienta de IA generativa Concierge tiene 30.000 usuarios; los ahorros de eficiencia financian la I+D.

## Últimos resultados

En el H1 2026 las ventas netas subieron un 15,7 % a tipos de cambio constantes hasta 22.106 millones de euros, impulsadas por Dupixent (9.324 millones de euros, +34,4 %), ALTUVIIIO y Ayvakit, mientras que las vacunas cayeron un 1,1 %. El resultado operativo de las actividades creció un 16,7 % hasta 6.258 millones de euros y el BPA de las actividades un 17,1 % hasta 3,97 euros, pero el beneficio neto IFRS bajó a 1.957 millones de euros tras un deterioro de 952 millones de euros en amlitelimab y costes de reestructuración. En el T2 2026 Dupixent superó por primera vez los 5 mil millones de euros en un trimestre, con 5.154 millones de euros. La deuda neta subió a 15.513 millones de euros tras la adquisición de Dynavax, el dividendo y las recompras de acciones. La previsión se elevó a un crecimiento de las ventas de en torno al 10 % a tipos de cambio constantes en 2026, con un BPA de las actividades que crece algo más deprisa.

## Inversiones y operaciones

- **Adquisiciones de 2025**: Blueprint Medicines (unos 9,1 mil millones de dólares de capital), Vicebio (1,15 mil millones de dólares por adelantado), Vigil Neuroscience (unos 470 millones de dólares) y Dren-0201 (539 millones de euros por adelantado); las adquisiciones de más de 500 millones de euros usaron 10.986 millones de euros de efectivo.
- **Dynavax**: Cerrada el 10 de febrero de 2026 por unos 2,2 mil millones de dólares, aportó la vacuna contra la hepatitis B Heplisav-B y un candidato contra el herpes zóster.
- **Compromiso de fabricación en Estados Unidos**: Con el acuerdo MFN del 19 de diciembre de 2025, Sanofi reafirmó una inversión de 20 mil millones de dólares en fabricación estadounidense a cambio de una exención arancelaria de tres años.
- **Inversiones y recompras de acciones**: Inversiones de 1.762 millones de euros en inmovilizado material en 2025, con unos 1,75 mil millones de euros al año previstos a medio plazo; una recompra de acciones de 1 mil millones de euros se completó en abril de 2026.
- **Desinversiones**: La participación de control del 50 % de Opella se vendió a CD&R por 10,4 mil millones de euros de efectivo neto, Enjaymo pasó a Recordati y la unidad brasileña de genéricos Medley está en venta.

## Retos y riesgos

- **Precios de medicamentos en Estados Unidos**: El acuerdo MFN conlleva recortes de precios del 61 % en medicamentos seleccionados y un tope de 35 dólares para la insulina, y los modelos CMS GLOBE y GUARD podrían tener un efecto adverso significativo.
- **Reveses en la cartera de investigación**: Los deterioros de tolebrutinib (1.663 millones de euros) en 2025 y amlitelimab (952 millones de euros) en 2026, además de programas interrumpidos, ponen bajo escrutinio la productividad de I+D.
- **Concentración en Dupixent**: El grupo depende en gran medida de Dupixent, cuya patente estadounidense del compuesto vence en marzo de 2031; el reparto de beneficios con Regeneron alcanzó 5.065 millones de euros en 2025.
- **Vacunas débiles y China**: Se espera que las vacunas bajen ligeramente en 2026 por las menores tasas de vacunación en Estados Unidos, y las ventas en China cayeron un 3,5 % en el H1 2026 porque el menor número de nacimientos afectó a las vacunas pediátricas.
- **Erosión por genéricos y reembolso de Regeneron**: La erosión por genéricos costó 353 millones de euros de ventas en 2025, y el fin del reembolso del desarrollo por parte de Regeneron deja una brecha neta de 200 millones de euros en el resultado operativo de las actividades en 2027.

## Lo que dice la dirección

> "My first months as CEO have focused on assessing the challenges facing Sanofi and working on an accelerated transformation roadmap that leverages our commercial strengths and focuses on the need for R&D and pipeline improvements" — Belén Garijo, Chief Executive Officer, Comunicado de prensa sobre los resultados del T2 2026, 30 de julio de 2026

> "It is also absolutely imperative that we intensify our business development and M&A activity in a disciplined way." — Belén Garijo, Chief Executive Officer, Conferencia con analistas sobre los resultados del T2 2026, 30 de julio de 2026

> "Our current focus is Dupixent, one. Two, Dupixent. Three, Dupixent." — Belén Garijo, Chief Executive Officer, Conferencia con analistas sobre los resultados del T2 2026, 30 de julio de 2026

> "take some time to make the right diagnostic" — Olivier Charmeil, Interim CEO and EVP General Medicines, Conferencia con analistas sobre los resultados del T1 2026, 23 de abril de 2026, consejo al futuro consejero delegado


## Dónde puede ayudar un proveedor

- **Operaciones clínicas y diseño de ensayos**: El impulso al rigor en I+D y a operaciones clínicas de extremo a extremo, desde el diseño del estudio hasta la conclusión del ensayo, abre espacio para CRO, analítica de ensayos y herramientas de apoyo a la decisión.
- **Licencias y apoyo al desarrollo de negocio**: La intensificación del desarrollo de negocio y de las fusiones y adquisiciones, incluida la licencia de entrada de innovación china, requiere socios de due diligence científica, asesoría en operaciones y gestión de alianzas.
- **Capacidad de fabricación en Estados Unidos**: La inversión reafirmada de 20 mil millones de dólares en fabricación estadounidense apunta a una demanda de ingeniería de plantas de biológicos, equipamiento y fabricación por contrato.
- **Acceso al mercado y analítica de precios**: Los precios MFN, la negociación de la IRA y los modelos CMS aumentan la necesidad de analítica de bruto a neto, descuentos y acceso al mercado.
- **Plataformas de IA y datos**: La agenda de eficiencia impulsada por IA de Sanofi, con Plai y herramientas de IA generativa de uso generalizado, favorece a los proveedores de IA, datos y automatización en I+D y fabricación.

_Lectura de Tamtam de las prioridades y los retos anteriores, no palabras de la propia empresa._

## Documentos clave

### [Annual Report on Form 20-F 2025](https://www.sanofi.com/assets/dotcom/content-app/publications/annual-report-on-form-20-f/2025-01-01-form-20-f-2025-en.pdf)

Informe anual · 2026-02-17

- Sanofi describes itself as "an R&D driven, AI-powered biopharma company"; it reports a single operating segment, Biopharma (Specialty Care, General Medicines and Vaccines franchises), organised around Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines. Consumer healthcare (Opella) was deconsolidated on 30 April 2025: a 50% controlling stake sold to CD&R, Sanofi keeps 48.2%, €10.4bn net cash proceeds, €2.6bn net gain.
- FY2025 net sales €43,626m, +6.2% reported and +9.9% at constant exchange rates (CER); business operating income €12,149m (vs €11,343m); business net income €9,555m (+7.2%); business EPS €7.83 (+10.0%); IFRS net income €7,813m (EPS €6.40, including the Opella gain); proposed dividend €4.12 per share (52.6% payout).
- Dupixent (with Regeneron) is the engine: €15,714m, +25.2% CER (US €11,538m, +26.7%); the US is 50.8% of group sales (€22,176m, +16.3% CER) while Europe is €9,169m (+1.6%) and Rest of World €12,281m (+5.6%, China €2,621m, +2.0%). Regeneron profit-sharing and related expenses reached €5,065m.
- Launches generated €5,721m (+34.0% CER): ALTUVIIIO €1,160m (+77.6%), Nexviazyme €790m (+21.4%), Sarclisa €588m (+28.5%), Rezurock €490m, Ayvakit €305m (consolidated since mid-July 2025), Cablivi €271m, Xenpozyme €228m. Vaccines were €7,936m (-1.2% CER): Beyfortus €1,781m (+9.5%), influenza/COVID €2,314m (-5.8%), PPH & boosters €2,554m (-4.4%).
- 2025 was an acquisition year: Blueprint Medicines (~$9.1bn equity, up to $9.5bn with CVRs), Vicebio ($1.15bn upfront), Vigil (~$470m), Dren-0201 (€539m upfront, up to €1.2bn milestones), plus the agreed Dynavax deal (~$2.2bn, closing Q1 2026); acquisitions above €500m consumed €10,986m of cash. €5bn of buybacks (incl. €3bn from L'Oréal) and €4,772m of dividends; net debt rose to €11,008m (gearing 15.4%); free cash flow €8,089m (vs €5,955m).
- Strategy ("Play to Win", relaunched in 2025 as "Take the Lead"): focus on growth (Dupixent, launches, four vaccine franchises), lead with innovation (immunology-centred "immuno-science" R&D, external deals), accelerate efficiency (AI platform Plai used by 22,000+ employees; GenAI Concierge 30,000 users) and reinvent how we work. Capital allocation order: organic growth, bolt-on BD/M&A, growing dividend, anti-dilutive buybacks.
- R&D spend €7,842m (18.0% of sales; 9,274 R&D employees out of 74,846 staff); 2025 pipeline readouts included positive Phase 3s for amlitelimab in atopic dermatitis and a €1,663m impairment on tolebrutinib after the failed PERSEUS study in PPMS.
- Headwinds flagged for 2026: the voluntary US "most favored nation" agreement signed 19 December 2025 (Medicaid prices aligned with high-income countries, 61% average cuts on selected diabetes/cardiovascular/neurology/cancer drugs, up to 70% discounts via TrumpRx, $35 insulin cap, in exchange for a three-year tariff exemption and a reaffirmed $20bn US manufacturing investment), IRA Medicare negotiation, CMS GLOBE/GUARD models, generic erosion (€353m lost in 2025), China VBP tenders and shifting US vaccine policy.
- Operations: ~60 countries with business operations, products in 160+ countries, ninth-largest pharma group by sales (US rank 12, 2.2% share; France rank 6, 4.0%); most production in-house, 37 industrial sites in 19 countries, vaccine sites in France, the US, Canada, India, Mexico and China.
- Leadership change recorded in the filing: on 11 February 2026 the Board relieved Paul Hudson of his duties as CEO effective 17 February 2026 and appointed Belén Garijo to succeed him after the 29 April 2026 AGM; Olivier Charmeil (EVP General Medicines) serves as interim CEO from 18 February; the Executive Committee has 12 members as of 17 February 2026.

### [Half-Year Financial Report 2026](https://www.sanofi.com/assets/dotcom/content-app/publications/half-year-financial-reports/half-year-financial-report-2026.pdf)

Informe intermedio · 2026-07-30

- H1 2026 net sales €22,106m, +11.1% reported and +15.7% at CER (currency cost 4.6 points), driven by Dupixent (€9,324m, +34.4% CER), Ayvakit (€367m) and ALTUVIIIO (€674m, +32.3%); launches reached €3,047m (+51.8%).
- Business operating income €6,258m (+16.7%, 28.3% of sales); business net income €4,765m (+14.8%); business EPS €3.97 (+17.1%). IFRS net income fell to €1,957m from €5,812m because H1 2025 carried the €2,693m Opella gain and H1 2026 carries a €952m amlitelimab impairment and €563m of restructuring; IFRS EPS €1.63.
- Geography: US €11,633m (+29.9% CER), Europe €4,304m (+3.6%), Rest of World €6,169m (+1.9%), China €1,325m (-3.5%, falling birth rate hitting paediatric vaccines). Vaccines €2,443m (-1.1%): PPH incl. newly acquired Heplisav-B €1,364m (+2.8%), Beyfortus €392m (+13.2%), influenza/COVID €121m (-42.1%).
- Cash and balance sheet: free cash flow €3,724m (€2,458m); net debt up to €15,513m from €11,008m after the Dynavax acquisition (€1,403m cash), the €4,923m dividend and €1,003m of buybacks (12.57m shares); gearing 22.3%; €2.3bn bond issued in April; equity €69,567m.
- Governance reset: the Board did not renew Paul Hudson (CEO relieved 17 February 2026), Olivier Charmeil served as interim CEO from 18 February to 30 April, Belén Garijo is CEO since 1 May 2026; the AGM of 29 April approved a €4.12 dividend; a slimmer eight-member Executive Committee applies from 1 September 2026 (Roger finance, Paulo Fontoura R&D, Buxo specialty care, Triomphe vaccines, Grenier general medicines, O'Callaghan manufacturing, Haney legal, Jaillet interim people).
- Pipeline decisions: amlitelimab will not be filed (24 July 2026); itepekimab (COPD, CRS) discontinued with Regeneron; riliprubart MOBILIZE stopped; Dupixent failed in lichen simplex chronicus and the EU bullous pemphigoid file was withdrawn. Positives: Dupixent approvals in AFRS (US) and paediatric CSU (US/EU), Tzield expansions, Cenrifki approved in the EU for non-relapsing SPMS, Sarclisa subcutaneous approved in the EU, US and Japan, Nexviazyme Baby-COMET success, venglustat priority review (FDA date 25 November 2026), efdoralprin alfa filing planned H2 2026.
- Outlook raised: 2026 sales now expected to grow around 10% at CER, business EPS slightly faster; currency impact estimated at about -1% on sales and -2% on business EPS at July 2026 rates. R&D €3,980m (18.0% of sales, including over €200m of wind-down costs), SG&A €4,792m (21.7%).
- Access and sustainability: Impact not-for-profit medicines now in 30 countries, Global Health Unit reaching 6.6m beneficiaries across 40 countries; acoziborole (single-dose sleeping sickness treatment) approved in the DRC; Action 2026 employee share plan offered to ~75,000 employees in 52 countries at €59.87.

### [Q2 2026 results press release: double-digit sales growth, 2026 guidance upgraded](https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-07-30-05-30-00-3335767-en.pdf)

Informe intermedio · 2026-07-30

- Q2 2026 net sales €11,597m, +17.8% at CER (+16.0% reported); business operating income €3,291m (+35.8%, margin 28.4%, +3.8 points); business EPS €2.09 (+33.3% CER); IFRS EPS €0.29 (net income €343m, -91.3%, after a €1,031m impairment mainly on amlitelimab and €444m of restructuring); free cash flow €2,670m (+86.8%).
- Dupixent €5,154m (+37.6%), above €5bn in a quarter for the first time; US €3,899m (+42.8%) helped by demand, operational improvements and a favourable gross-to-net adjustment; Europe €583m (+19.4%); Rest of World €672m (+26.9%).
- Pharma launches €1,305m (+48.3%): ALTUVIIIO €349m (+23.7%), Sarclisa €187m (+35.7%), Ayvakit €190m ($221.3m, +26.4% pro forma, held back by higher US rebates), Nexviazyme €218m, Rezurock €163m, Cablivi €85m, Wayrilz €17m, Qfitlia €7m. Vaccines €1,150m (-4.7%): influenza/COVID €54m (-61.7%) on 2025 one-offs, Beyfortus €108m (+54.2%), PPH incl. Heplisav-B €700m (+1.4%; US +77.2%).
- Geography: US €6,344m (+33.5%), Europe €2,141m (+1.3%), Rest of World €3,112m (+3.7%), China €676m (-4.9%, paediatric vaccines hit by fewer births; pharma up low single digits on Sarclisa, Rezurock, Myqorzo and Dupixent).
- Costs: R&D €2,233m (+17.9%, including over €200m of pipeline wind-down costs), SG&A €2,465m (+9.0%, Blueprint and Dynavax consolidation); gross margin 81.2% (+3.7 points, including a >€200m Sarclisa SC provision reversal); Regeneron profit-sharing €1,972m; effective tax rate 21.7%, now expected around 21% for 2026.
- Pipeline: seven approvals (Dupixent paediatric CSU in the US, Tzield stage 3 T1D in the US, Wayrilz ITP in Japan, Sarclisa SC in the US, EU and Japan, Cenrifki SPMS in the EU), submissions accepted for Dupixent AFRS in Japan and venglustat GD3 in the US, EU and Japan, positive Phase 3s for Nexviazyme (infantile Pompe) and amlitelimab maintenance, but amlitelimab will not be filed and itepekimab and balinatunfib are discontinued; Dupixent failed in lichen simplex chronicus; venglustat has an FDA action date of 25 November 2026; 61 projects in the pipeline, 36 of them new molecular entities.
- Guidance upgraded: 2026 sales growth around 10% at CER (from high single digits), business EPS slightly faster than sales; currency about -1% on sales and -2% on EPS. CEO Belén Garijo cites an "accelerated transformation roadmap" and a 2030 ambition of around €25bn Dupixent sales plus about €10bn from pharma launches.
- Capital: €1bn buyback completed in April; dividend €4.12 (31 consecutive increases); net debt €15,513m at 30 June (from €10,988m) after Dynavax (€1,635m), buyback (€1,009m) and the €4,923m dividend; Q3 2026 results due 30 October 2026.

### [Q2 2026 earnings call: Belén Garijo's first call as CEO (LSEG transcript)](https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2026/2026-q2-2026-results/SAN-EP_Transcript_2026-07-30.pdf)

Intervención de un directivo · Belén Garijo, Chief Executive Officer (with François-Xavier Roger, CFO, and Michael Quigley, Chief Scientific Officer) · 2026-07-30

- Twelve weeks in, Garijo says she has "completed the critical phase of my diagnosis": Sanofi has strong commercial execution (Q2 sales +17.8% CER, business EPS +33.3%) but must fix R&D productivity "with the right sense of urgency"; an enterprise-level strategy will be shared "over the coming months and latest by the end of the year".
- R&D diagnosis: "we need greater scientific rigor, fact-based decision-making, a stronger [...] governance, and more effective operations"; she blames setbacks on Phase 2-to-Phase 3 decisions that "start by dreaming on a target product profile that is not based on rigorous assumption", wants scientists to own go/no-go calls, and has launched an outside-in portfolio review (amlitelimab, itepekimab and balinatunfib already cut; "we don't have a target number to discontinue"). Paulo Fontoura becomes head of R&D in September; R&D spend will grow moderately, below sales, in the short term.
- BD and M&A will be intensified: "our appetite for bigger deals is an option" subject to strategic fit, science and financial guardrails; focus on disease areas where Sanofi is strong (dermatology, respiratory, rare diseases), with no barriers related to Regeneron to moving forward on M&A and, per Charmeil, "no urgency -- dramatic urgency" on timing. Roger, who now also owns BD, notes Sanofi invested €47bn in BD/M&A over eight years and "lost" about €7bn of it.
- Regeneron alliance is "of strategic importance"; Garijo found trust lacking and is rebuilding it with Manuela Buxo; options include adding assets from both sides and improving agility; the narrow information-sharing litigation does not block talks. On Dupixent, "Our current focus is Dupixent, one. Two, Dupixent. Three, Dupixent."
- China is a priority: "we have lost a bit of momentum in China"; Thomas Triomphe will lead China from 1 September, both to sell into a large-volume market and to in-license Chinese innovation. Rare diseases (top-2/3 position) are seen as a larger opportunity beyond genetic disorders; businesses that do not become growth platforms could be partnered or sold.
- 2030 ambition updated at today's less favourable rates: Dupixent around €25bn, pharma launches about €10bn (needs a ~15% CAGR versus ~27% like-for-like growth in H1; launches should reach €5.2-5.3bn in 2026 and are already profitable), vaccines about €9bn (down €1bn: half FX, half weaker US vaccination rates after the administration change). Dupixent patents run to 2046; the planning base case remains the March 2031 US compound patent expiry.
- Financial mechanics from the CFO: 2026 guidance raised to ~10% sales growth at CER with EPS slightly faster; Q2 Dupixent included "a couple of hundred millions" of one-off gross-to-net benefit (partly 340B controls, partly recurring); H2 growth will slow on tough comparables; Q3 vaccine sales expected down low-to-mid teens; Regeneron development reimbursement ended in Q2, leaving a €200m net BOI gap in 2027 (-€600m reimbursement, +€400m Amvuttra royalties); 2026 tax rate ~21%.
- Culture and organisation: a "performance-driven culture, greater accountability", empowered country leaders in "a de-globalizing market", and an eight-member ComEx from 1 September with three new members. On investor credibility: "we have, for a period of time, over promise and under deliver."

### [Q1 2026 earnings call with interim CEO Olivier Charmeil, CFO François-Xavier Roger and R&D head Houman Ashrafian (LSEG transcript)](https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2026/2026-q1-2026-results/SAN-EP_Transcript_2026-04-23.pdf)

Intervención de un directivo · Olivier Charmeil, Interim CEO and EVP General Medicines (with François-Xavier Roger, CFO, and Houman Ashrafian, EVP Head of R&D) · 2026-04-23

- Held one week before Belén Garijo's arrival, with Olivier Charmeil as interim CEO after Paul Hudson's departure (CEO 2019-2026): Q1 2026 sales €10.5bn, +13.6% at CER (about 12% like-for-like), business EPS +14%, BOI +10.9%, OpEx +7% but down 1.9 points as a share of sales; 2026 guidance of high single-digit sales growth with EPS slightly faster was confirmed (later raised in July).
- Growth drivers: launches were 14% of sales and grew 44% (about 22% excluding acquisitions): ALTUVIIIO €325m (+42%), Beyfortus €284m, Sarclisa €167m (+30%), Ayvakit €170m, Heplisav-B €46m since the February Dynavax closing; rare diseases nearly €1.8bn (+20%); vaccines €1.3bn; Dupixent approaching €4.2bn (+31%, flattered by a low US base), now nine indications and 1.4 million patients.
- First public Defend / Extend / Innovate plan for Dupixent's loss of exclusivity: patents from 2031 to 2045 (50+ US patents, none yet challenged) to be "vigorously" defended beyond the March 2031 US compound expiry; a four-weekly dosing option through a higher-dose asthma programme and a hyaluronidase co-formulation with a partner (studies from H2 2026); and new molecules through the Regeneron alliance, including an IL-4R alpha follow-on. Roger: the slide reflects investor appetite, "I don't think there is any defensive view on that matter."
- Capital allocation: Roger says Sanofi can invest up to €15bn in BD/M&A this year while keeping its AA rating, potentially €10bn more if it buys commercialised assets; priority areas are immunology, rare diseases and vaccines, with late-stage assets not excluded; BD did not pause pending the new CEO. About €400m of capital gains expected in 2026; the Brazilian generics unit Medley was signed for sale in March (closing around end-2026); the €1bn buyback was about to complete.
- Regeneron development reimbursement ends around Q2 2026: a negative BOI impact of about €400m in 2026 and a further ~€700m in 2027, which Sanofi says it will absorb while growing BOI in margin and absolute terms.
- Pipeline at the time: amlitelimab Phase 3 data presented at AAD with two cutaneous Kaposi's sarcoma cases among ~4,500 patients, management still "confident in the benefit risk" and planning an H2 2026 filing (later abandoned); lunsekimig positive Phase 2 in asthma and CRSwNP, Phase 3 next; duvakitug maintenance data; venglustat positive in Gaucher type 3 but failed in Fabry; itepekimab COPD Phase 3 decision pending with regulators and Regeneron; new in-licensing of rovadicitinib (Sino Biopharm) and a Kali Therapeutics T-cell engager.
- Charmeil's advice to the incoming CEO: "take some time to make the right diagnostic", then "be decisive"; the company has "considerably changed in the last 5 to 10 years", with better prioritisation and stronger US commercial capabilities. Buxo on competition: atopic dermatitis is "barely above 18% advanced therapy penetration", so new entrants expand the market.

## Preguntas sobre Sanofi

### ¿Qué hace Sanofi?

Sanofi desarrolla, fabrica y vende medicamentos y vacunas en inmunología, enfermedades raras, neurología, oncología y vacunas; Dupixent es su mayor producto.

### ¿Cuáles son los ingresos de Sanofi?

Las ventas netas del ejercicio 2025 fueron de 43.626 millones de euros, un 9,9 % más a tipos de cambio constantes; las del H1 2026 fueron de 22.106 millones de euros.

### ¿Cuántos empleados tiene Sanofi?

74.846 a finales de 2025, tras el traspaso de la plantilla de Opella.

### ¿Quién es el consejero delegado de Sanofi?

Belén Garijo es consejera delegada desde el 1 de mayo de 2026, en sustitución de Paul Hudson; François-Xavier Roger es director financiero.

### ¿Cuál es la estrategia de Sanofi?

Hacer crecer Dupixent y los nuevos lanzamientos, corregir la productividad de I+D mediante una revisión del portfolio, intensificar el desarrollo de negocio y las fusiones y adquisiciones en sus áreas de enfermedad más fuertes y recuperar impulso en China.

_Redactado por Tamtam a partir de los documentos publicados por la propia empresa, enumerados arriba y leídos íntegramente. Las cifras son las de esos documentos, para los periodos que indican. (2026-11-17)_
